Madrigal Pharmaceuticals, Inc. (MDGL)

CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on ...

Summit Therapeutics has an incredibly promising cancer candidate in the pipeline. Madrigal Pharmaceuticals made a breakthrough that could drive strong results for years to come....

CONSHOHOCKEN, Pa., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?...

Ameritas Investment Partners Inc. lessened its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 6.1% during the second quarter, according to the company in its most recent 13F fi...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL - Get Free Report)'s stock price reached a new 52-week high on Monday after HC Wainwright raised their price target on the stock from $568.00 to $620.00. H...

CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...

Madrigal Pharmaceuticals, Inc. ( MDGL ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:30 AM EST Company Participants William Sibold - CEO, President & Director Mardi Dier - Executive...

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor confer...

Insights from John Paulson (Trades, Portfolio)'s Third Quarter 2025 13F Filing John Paulson (Trades, Portfolio) recently submitted the 13F filing for the third...